PATH, Seattle, WA 98109, USA.
Vaccine. 2012 Nov 26;30(50):7134-40. doi: 10.1016/j.vaccine.2012.09.034. Epub 2012 Sep 29.
Immunization of pregnant women against influenza is a promising strategy to protect the mother, fetus, and young infant from influenza-related diseases. The burden of influenza during pregnancy, the vaccine immunogenicity during this period, and the robust influenza vaccine safety database underpin recommendations that all pregnant women receive the vaccine to decrease complications of influenza disease during their pregnancies. Recent data also support maternal immunization for the additional purpose of preventing disease in the infant during the first six months of life. In April 2012, the WHO Strategic Advisory Group of Experts (SAGE) on Immunization recommended revisions to the WHO position paper on influenza vaccines. For the first time, SAGE recommended pregnant women should be made the highest priority for inactivated seasonal influenza vaccination. However, the variable maternal influenza vaccination coverage in countries with pre-existing maternal influenza vaccine recommendations underscores the need to understand and to address the discrepancy between recommendations and implementation success. We present the outcome of a multi-stakeholder expert consultation on inactivated influenza vaccination in pregnancy. The creation and implementation of vaccine policies and regulations require substantial resources and capacity. As with all public health interventions, the existence of perceived and real risks of vaccination will necessitate effective and transparent risk communication. Potential risk allocation and sharing mechanisms should be addressed by governments, vaccine manufacturers, and other stakeholders. In resource-limited settings, vaccine-related issues concerning supply, formulation, regulation, evidence evaluation, distribution, cost-utility, and post-marketing safety surveillance need to be addressed. Lessons can be learned from the Maternal and Neonatal Tetanus Elimination Initiative as well as efforts to increase vaccine coverage among pregnant women during the 2009 influenza pandemic. We conclude with an analysis of data gaps and necessary activities to facilitate implementation of maternal influenza immunization programs in resource-limited settings.
孕妇流感免疫接种是保护母亲、胎儿和婴儿免受流感相关疾病的一项有前景的策略。妊娠期流感的负担、该时期疫苗的免疫原性以及强大的流感疫苗安全性数据库为所有孕妇接种疫苗以降低妊娠期流感疾病并发症的建议提供了依据。最近的数据还支持孕妇接种疫苗,以额外预防婴儿在生命最初 6 个月内患病。2012 年 4 月,世界卫生组织免疫战略咨询专家组(SAGE)建议修订世界卫生组织关于流感疫苗的立场文件。这是 SAGE 首次建议将孕妇列为季节性流感灭活疫苗的最高优先接种人群。然而,在已经存在孕妇流感疫苗建议的国家中,孕妇流感疫苗接种覆盖率各不相同,这突出表明需要了解和解决建议与实施成功之间的差距。我们介绍了一次关于孕妇接种灭活流感疫苗的多方利益攸关方专家协商的结果。疫苗政策和法规的制定和实施需要大量的资源和能力。与所有公共卫生干预措施一样,疫苗接种的感知和实际风险将需要有效的和透明的风险沟通。潜在的风险分配和分担机制应由政府、疫苗制造商和其他利益攸关方来解决。在资源有限的情况下,需要解决与供应、配方、监管、证据评估、分配、成本效益以及上市后安全性监测有关的疫苗相关问题。可以从消除孕产妇和新生儿破伤风倡议以及在 2009 年流感大流行期间提高孕妇疫苗接种率的努力中吸取经验教训。最后,我们分析了数据差距,并为在资源有限的情况下促进孕妇流感免疫计划的实施确定了必要的活动。